The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC).
Leonidas Chelis
No relevant relationships to disclose
Savas Deftereos
No relevant relationships to disclose
Nikolaos Xenidis
No relevant relationships to disclose
Kiriakos Amarantidis
No relevant relationships to disclose
Eleni Kyrillos Hamalidou
No relevant relationships to disclose
Prokopios Dimopoulos
No relevant relationships to disclose
Prodromos Michailidis
No relevant relationships to disclose
Evagelos Christakidis
No relevant relationships to disclose
Kostantinos Mimidis
No relevant relationships to disclose
Dimitra Pitsiava
No relevant relationships to disclose
Anastasios Karayiannakis
No relevant relationships to disclose
Stylianos Kakolyris
No relevant relationships to disclose